Walleye Capital’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Walleye Capital’s Portfolio BIOS Stock Details BIOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-373,682	Closed	-$4.05M	–	5802
2023 Q3	$4.05M	Hold	373,682	–	–	0.01%	1180
2023 Q2	$3.98M	Buy	373,682 +309,897	+486%	+$3.26M	0.01%	878
2023 Q1	$666K	Hold	63,785	–	–	0.01%	1458
2022 Q4	$652K	Hold	63,785	–	–	0.01%	1286
2022 Q3	$641K	Hold	63,785	–	–	0.01%	1298
2022 Q2	$634K	Hold	63,785	–	–	0.02%	899
2022 Q1	$630K	Buy	+63,785	New	+$629K	0.02%	900

Walleye Capital's BIOS Position: Q4 2023 in Review

Walleye Capital sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2023, closing a stake of 373,682 shares — an estimated $4.05M sold.

Walleye Capital first reported a position in BIOS in Q1 2022 and held it in 7 quarters. The position peaked at $4.05M in Q3 2023. 0 funds tracked by Wall St. Rank hold BIOS as of Q4 2023.

Walleye Capital reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2023 after selling out during the quarter.
Walleye Capital sold 373,682 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2023, an estimated $4.05M.
Walleye Capital first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 7 quarters.
Walleye Capital's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $4.05M in Q3 2023.
0 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2023.

Based on Walleye Capital's 13F filing for Q4 2023, filed 14 Feb 2024.